FINWIRES · TerminalLIVE
FINWIRES

Affirm Makes 'Strong Case' for Updated Medium-Term Growth Targets, RBC Says

By

Affirm (AFRM) presented a "strong case" for achieving its updated "medium-term growth targets," driven by merchant point-of-sale financing, direct-to-consumer expansion and international growth, RBC Capital Markets said in a note Wednesday.

The company is targeting $100 billion in gross merchandise volume, up from about $46 billion currently, while also forecasting stronger revenue margins and annual GAAP earnings per share of about $3 to $4. It also highlighted the Affirm "Card," enterprise merchant expansion and international partnerships as "key growth drivers," according to the note.

Affirm's funding model is becoming a "competitive advantage" as the company scales, lowering funding costs through its network of about 200 "unique funding partners." A pending industrial bank charter could further strengthen the company's funding capabilities through deposits and loan origination, RBC said.

RBC also pointed to "emerging opportunities" in agentic commerce and Affirm Edge, which embeds buy now, pay later services into banking apps through partnerships with "large commerce" companies.

RBC has a sector perform rating on Affirm, with a price target of $80.

Price: $63.78, Change: $-1.65, Percent Change: -2.52%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP